Biology Digest

  FRANKFURT, June 29 (Reuters) - BioNTech  (22UAy.DE)  and its U.S. partner OncoC4 Inc say they have started a late-stage study of their lung cancer immunotherapy candidate as the German COVID-19 vaccine maker seeks to advance its traditional focus on oncology drug development. The Phase III trial, which can potentially lead to a regulatory filing, will enrol about 600 patients, the companies said in a statement on Thursday. It will seek to show a benefit for people suffering from metastatic non-small cell lung cancer, which has progressed despite treatment with so-called checkpoint inhibitor drugs such as Merck & Co's  (MRK.N)  Keytruda. Earlier this month, a mid-stage trial showed that the drug candidate known as  gotistobart  shrunk tumours in close to 30% of study participants. https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-oncoc4-start-late-stage-lung-cancer-drug-trial-2023-06-29/ https://www.cnbc.com/2023/06/05/moderna-cancer-vaccine-with-merck-keytr

  There’s hope for treating one of the   deadliest forms of cancer.  A pancreatic cancer vaccine has proven to be effective in half of patients treated in a small trial, according to a study published in the  journal Nature  on Wednesday. Pancreatic cancer — often  called the “silent killer,”  since symptoms don’t show up in most patients until it has spread to other organs — occurs when cells in the pancreas mutate and form a tumor. Memorial Sloan Kettering Cancer Center in New York sent tumor samples from 16 patients to scientists at  BioNTech in Germany,  the same company Pfizer teamed up with to produce COVID-19 vaccines.  After scientists analyzed proteins in patient’s cancer cells, they used messenger RNA — a molecule that contains instructions to direct cells to make a protein — in a vaccine for each patient, attempting to tell the immune system to attack the cancer cells. Along with the vaccine, subjects were also given chemotherapy and a drug meant to keep tumors from combatti

  Researchers say they have successfully completed a trial of a personalised cancer vaccine that uses the same messenger-RNA technology as Covid jabs. The experimental vaccine, made by Moderna and MSD, is designed to prime the immune system to seek and destroy cancerous cells. Doctors hope work such as this could lead to revolutionary new ways to fight skin, bowel and other types of cancer. Moderna and MSD called it "a new paradigm" moment. Other pharmaceutical companies are looking to run similar studies. But this is the first phase-IIb randomised clinical trial to test the investigational mRNA vaccine in patients. Could Covid vaccine technology crack cancer? Patients taking Keytruda for advanced melanoma were less likely to die, or have the skin cancer reoccur, if they also had the jab, mRNA-4157/V940, Moderna and MSD said. The findings, in 157 patients, have not yet been scrutinised by independent experts or regulators. More trials will be needed to check how effective the

  SANTIAGO, March 29 (Reuters) - Chile detected the first case of bird flue in a human, the country's health ministry reported on Wednesday. The case was detected in a 53-year-old man who presented severe influenza symptoms, according to a statement issued by the ministry, but they noted the patient was in stable condition. The government is also investigating the source of contagion as well as others who were in contact with the patient. Chile has reported cases of the H5N1 bird flu since late last year in wild animals. Recent cases in industrial farms caused the government to halt poultry exports. Industrial cases have also been  detected in Argentina , but Brazil, the world's largest exporter of poultry, remains free of the contagion. Chilean health authorities noted the virus can be transmitted from birds or marine mammals to humans, but there is no known human-to-human transmission. Earlier this year, Ecuador confirmed its first case of human transmission of  bid flu in a

Human bodies are needed to advance medical science and many tissue banks that distribute bodies donated to science provide a valuable service. But unlike organ donation, this market is for-profit and largely unregulated, creating opportunities for bad actors to mislead families or outright con people out of their loved ones' remains to line their pockets. In this eye-opening documentary, CBS Reports goes inside the $100 million market where bodies donated to science are bought and sold for profit.  

Farewell to the Foldit Crew